<DOC>
	<DOCNO>NCT02433236</DOCNO>
	<brief_summary>Phase 2 , multi-center , open label extension study evaluate 2 dose regimen fostamatinib approximately 25 subject . The study consist 11 visit 15 month .</brief_summary>
	<brief_title>Open Label Study Fostamatinib Treatment IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>Completed Study C938788050 , include receive posttreatment renal biopsy , clinically meaningful response ( i.e . decrease proteinuria improve renal histology ) Able willing give write informed consent Unresolved Grade 2 great toxicity Study C935788050</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>